Manuel Hidalgo, M.D., Ph.D., Scientific Advisor, European Strategy Consultant. Manuel Hidalgo was born in Antequera, Malaga, in 1968. He received his MD from the Universidad de Navarra, Pamplona, in 1992 and his PhD from the Universidad Autonoma de Madrid in 1997. Manuel specialised in Medical Oncology at the Hospital Universitario 12 de Octubre, Madrid, obtaining his license in 1996. He completed his training in drug development at the University of Texas Health Science Center, San Antonio (USA), where he briefly joined as Faculty. He then moved to Johns Hopkins University in 2001 as Co-Director of the Drug Development and GI Programmes. He joined the CNIO in 2009 to lead the GI Cancer Clinical Research Unit. Manuel is a founding member of the pancreatic cancer research team – a clinical trials group focusing on novel therapeutics for pancreatic cancer. He has participated in the clinical development of more than 30 novel anticancer agents and led the early clinical trials with erlotinib and temsirolimus – two recently approved drugs. Manuel´s work has contributed to the incorporation of molecular endpoints in early clinical trials. His group pioneered the utilisation of personalised xenograft models for drug screening, biomarker development and personalised cancer treatment. He has published more than 180 papers in peer-reviewed journals and his work has been funded by the NCI, AACR, and ASCO. Manuel received an AACR Clinical Research Fellowship and an ASCO Career Development Award for his work on the development of EGFR inhibitors. His most recent efforts focus on novel therapeutics for pancreatic cancer. In 2011, he was named Vice Director of Translational Research at CNIO charged with the mission to foster translational research at CNIO and with a broader implication of the Center in cancer care.
Ashok Saluja, Ph.D. Scientific Advisor. Dr. Saluja is a founder of the American Pancreatic Association, and an internationally recognized expert on pancreatitis and pancreatic cancer. Dr. Saluja is Vice Chair of the University of Minnesota Department of Surgery, and the recipient of numerous awards and honors in the fields of pancreatitis and pancreatic cancer.
Daniel D. Von Hoff, M.D., Scientific Advisor. Dr. Von Hoff led the clinical development of Abraxane®, the most recent FDA approved treatment for patients with pancreatic cancer. Dr. Von Hoff is Physician in Chief, and Distinguished Professor, Translational Genomics Research Institute (TGen) and Professor of Medicine, Mayo Clinic and Chief Scientific Officer Scottsdale Healthcare and US Oncology. Dr. Von Hoff has received the distinguished Karnosfsky award from the American Society of Clinical Oncology (ASCO), as well as numerous other awards and honors for his work in pancreatic cancer research. Dr. Von Hoff is widely acknowledged to be the world’s pre-eminent authority on pancreatic cancer.
Steven Pandol, M.D., Scientific Advisor. Dr. Pandol is immediate past president of the American Pancreatic Association, and Director, Basic & Translational Pancreas Research, Gastroenterology, Cancer Biology & Therapeutics at Cedars-Sinai Medical Center in Los Angeles. Dr. Pandol is widely recognized for his expertise in pancreatitis.
Raymond J. Bergeron, Ph.D., Scientific Advisor. Dr. Bergeron, the inventor of SBP-101 being commercialized by Sun BioPharma, Inc., is also the inventor of four (4) other compounds in human clinical trials and the holder of one hundred nineteen (119) patents. Over the past twenty-five (25) years, Dr. Bergeron has been engaged in research and development of polyamine analogues such as SBP-101 for potential use as anti-cancer agents. Dr. Bergeron’s research has been supported by funding under National Cooperative Drug Discovery Group grants from the National Cancer Institute (NCI) and to date he has raised about $130 million in grants at the University where he is the Graduate Professor of Medicinal Chemistry and Duckworth Eminent Scholar of Drug Development. He was recently selected as a Founding Fellow of the National Academy of Inventors. Dr. Bergeron holds an AB from Clark University in Worcester, Massachusetts and a Ph.D. from Brandeis University in Waltham, Massachusetts. Dr. Bergeron was also a postdoctoral fellow at Harvard University with Nobel Laureate Dr. Konrad Bloch.